Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + BR in Newly-diagnosed Waldenström's Macroglobulinemia
NCT05979948Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Aug 2023
- Primary completion
- Apr 2025
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in Waldenström's macroglobulinemia (WM), sponsored by Shanghai Changzheng Hospital. Started Aug 2023; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05979948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979948.